Immuneonco Biopharmaceuticals

Developer of therapeutic solutions for treating cancer

placeShanghai, Shanghai, China calendar_todayFounded 2015 groups152 employees language immuneonco.com

Investor mix

12 investors on record; lead investors include Shanghai Zhangjiang Technology Venture Capital, Greater Bay Area Homeland Investments, Lilly Asia Ventures, Lanxess Investment Group.

Investor typeCountShare
Venture capital758%
Private equity18%
Other / undisclosed433%
Coming soon